

ASX ANNOUNCEMENT**Actinogen Medical to Present at the SACHS Neuroscience Innovation Forum during JPM Week**

- Actinogen Medical will present and participate in partnering meetings at the 2nd Annual SACHS Neuroscience Innovation Forum during JPM Week in San Francisco, commencing on the 6th January
- The SACHS Neuroscience Innovation Forum and scheduled meetings over subsequent days offers Actinogen a global stage to showcase the excellent progress made with the development of Xanamem
- Latest Xanamem developments include; completion of patient enrolment into Alzheimer's study XanADu with results expected in less than 6 months, and the initiation of nine additional Xanamem studies
- The SACHS Neuroscience Innovation Forum brings together biotech companies focused on central nervous system conditions, with pharma partners and investors
- JPM Week attracts the global biopharmaceutical industry and biotech investors to San Francisco each year.

Sydney, 7 January 2019. Australian Biotech **Actinogen Medical (ASX: ACW)** will present at the SACHS Neuroscience Forum and participate in partnering meetings during the JPM week in San Francisco in January 2019, providing the Company with an opportunity to showcase the excellent progress made with the development of Xanamem and to engage with global investors and the scientific and medical communities.

Dr Bill Ketelbey, Actinogen's CEO, will present at the **2nd Annual SACHS Neuroscience Innovation Forum** on January 6, 2019. The SACHS Neuroscience Innovation Forum, provides an opportunity to update the pharma industry and major global investors interested in neuroscience on the Company's progress to date with the development of Xanamem, including XanADu in Alzheimer's disease, and the initiation of nine additional Xanamem studies over the past 6 months.

Following the SACHS Neuroscience Innovation Forum, Actinogen will participate in multiple partnering meetings during JPM Week (6th - 10th January), concurrent with the **37th Annual JP Morgan Healthcare Conference**, which is the preeminent global investment and business development conference focused on healthcare, attracting the pharmaceutical industry and investors to San Francisco from across the globe.

Meetings with prospective partners and investors will allow Actinogen to showcase the Company's excellent progress with the development of Xanamem, including the completion of patient enrolment into the Alzheimer's study XanADu, with the study results expected in less than 6 months from now. As previously announced, the Company not only reached this significant milestone with XanADu within the original timelines, but also exceeded the original patient target of 174 with a total of 186 patients enrolled. This is testament to the quality of execution across multiple aspects of the trial.

Attached is the latest Investor Presentation that will be utilised in the SACHS presentation and discussed in the various partnering meetings the Company will participate in.

If you are interested in a meeting with Actinogen in San Francisco from January 6-10, please contact Ben Walsh, whose contact details are set out on the following page.

ENDS

Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Investor and Media Enquiries

Ben Walsh

WE Buchan

M: +61 411 520 012

E: bwalsh@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. Results are expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.